title: [Status of cellular immunity in patients with Astrakhan fever].
abstract: OBJECTIVE
  To ascertain regularities of development of cellular immunity in patients with Astrakhan fever (AF) with reference to AF severity, treatment and course.
  
  
  METHODS
  Cellular factors of immunity--relative and absolute contents of T-lymphocytes (early and late), T-helpers and T-suppressors, B-lymphocytes, neutrophils (early and late)--were studied in 75 patients with AF (63 patients with moderate and 12 patients with severe disease) in the course of the disease progression (weeks 1-5). The patients received antibacterial treatment--doxicyclin, rifampicin and doxicycline in combination with alpha 2-realdiron and gamma-reaferon.
  
  
  RESULTS
  Examination of immunocompetent cells has revealed suppression of T- and B-immunity for 2 weeks in moderate AF and 3 weeks in severe AF. The number of T-helpers was low for 3 weeks while of T-suppressors rose beginning from week 2. Immunoregulatory index Tx/Tc remains low till the end of the disease. The number of early and late neutrophils increased since weeks 2 of the disease in moderate and week 3 in severe AF.
  
  
  CONCLUSIONS
  Doxicycline efficiency was higher than that of rifampicin. Interferon preparations decrease relative number of early and late T-lymphocytes, neutrocytes and T-helpers but their absolute number is at the control level. Relative content of T-suppressors and B-lymphocytes is as in controls but their absolute content is higher.
authors.forename: N B
authors.initials: NB
authors.lastname: Kasimova
authors.forename: I N
authors.initials: IN
authors.lastname: Kulikova
authors.forename: S F
authors.initials: SF
authors.lastname: Karpenko
authors.forename: V S
authors.initials: VS
authors.lastname: Burkin
authors.forename: S A
authors.initials: SA
authors.lastname: Altukhov
authors.forename: T E
authors.initials: TE
authors.lastname: Arshba
authors.forename: G S
authors.initials: GS
authors.lastname: Aĭrapetova
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D001402:B-Lymphocytes / Q000276:immunology*; D001907:Boutonneuse Fever / Q000188:drug therapy / Q000276:immunology*; D004318:Doxycycline / Q000627:therapeutic use; D006801:Humans; D007370:Interferon Type I / Q000627:therapeutic use; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D008875:Middle Aged; D011994:Recombinant Proteins; D012293:Rifampin / Q000627:therapeutic use; D013601:T-Lymphocytes / Q000276:immunology*
chemical_list: D007370:Interferon Type I; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins; D004318:Doxycycline; D012293:Rifampin